AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF THE CLAIMS

1. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a tissue protective cytokine; at least one anti-inflammatory agent; and a pharmaceutically acceptable carrier.

2. (Withdrawn) The pharmaceutical composition of claim 1, wherein the anti-inflammatory agent is selected from the group consisting of corticosteroids, glucocorticoids, steroids, non-steroidal anti-inflammatory drugs, beta-agonists, anticholinergic agents, methyl xanthines, gold injections, sulphasalazine, penicillamine, anti-angiogenic agents, dapsone, psoralens, anti-malarial agents, anti-viral agents, and antibiotics.

3. (Withdrawn) A pharmaceutical composition comprising a therapeutically effective amount of a tissue protective cytokine; at least one immunomodulatory agent; and a pharmaceutically acceptable carrier.

4. (Withdrawn) The pharmaceutical composition of claim 3, wherein the immunomodulatory agent is selected from the group consisting of methothrexate, leflunomide, cyclophosphamide, cytoxan, Immuran, cyclosporine A, minocycline, azathioprine, antibiotics, methylprednisolone, corticosteroids, steroids, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, malononitriloamindes, T cell receptor modulators, and cytokine receptor modulators.

5. (Withdrawn) A pharmaceutical composition of claim 1 or 3, wherein said tissue protective cytokine is selected from the group consisting of i) an erythropoietin that lacks sialic acid moieties; ii) an erythropoietin that lacks N-linked or lacks O-linked carbohydrates; iii) an erythropoietin having a reduced carbohydrate content by treatment of native erythropoietin with at least one glycosidase; iv) an erythropoietin having at least one or more oxidized carbohydrates; v) an erythropoietin comprising at least one or more oxidized carbohydrates which is chemically reduced; vi) an erythropoietin comprising at least one or more modified arginine residues; vii) an erythropoietin comprising at least one or more modified lysine residues or a modification of the N-terminal amino group of the erythropoietin molecule; viii) an erythropoietin comprising at least a modified tyrosine

residue; ix) an erythropoietin comprising at least a modified aspartic acid or a glutamic acid residue; x) an erythropoietin comprising at least a modified tryptophan residue; xi) an erythropoietin having at least one amino group removed; xii) an erythropoietin comprising at least an opening of at least one of the cystine linkages in the erythropoietin molecule; and xiii) a truncated erythropoietin.

6. (Canceled).

7. (Canceled).

8. (Currently amended) A method for treating an inflammatory disease in a mammal comprising responsive cells, said method comprising ~~(a)~~ administering to a mammal in need thereof a pharmaceutical composition comprising a prophylactically or therapeutically effective amount of ~~an~~ a chemically modified erythropoietin ~~having at least one of the modifications (i) to (v) below,~~ and an anti-inflammatory agent or a prophylactically or therapeutically effective amount of a chemically modified erythropoietin and an immunomodulatory agent,

wherein said modified erythropoietin has a reduced level of in vivo erythropoietic activity compared to native erythropoietin as determined by the exhypoxic polycythemic mouse bioassay, and has tissue protective activity in vivo as determined by the middle cerebral artery occlusion test

and wherein said chemically modified erythropoietin comprises:

i) ~~one or more~~ a chemically modified arginine residues at position 31, 37, 41, 80, 103, 130, 137, 158, 166, 170, 177, 189, or 193 of SEQ ID NO:5;

ii) ~~one or more~~ a chemically modified lysine residues at position 47, 72, 79, 124, 143, 167, 179, or 181 of SEQ ID NO:5 or a chemical modified ~~modification of the~~ N-terminal amino group;

iii) ~~one or more~~ a chemically modified tyrosine residues at position 42, 76, 172, or 183 of SEQ ID NO:5;

iv) ~~one or more~~ a chemically modified aspartic acid or a glutamic acid residues at position 35, 70, 123, 150, 163, 192, 40, 45, 48, 50, 58, 64, 82, 89, 99, 116, 144, or 186 of SEQ ID NO:5; and

v) ~~one or more~~ a chemically modified tryptophan residues at position 78, 91, or 115 SEQ ID NO:5,

wherein the chemical modification results from one of the following chemical reactions: accetylation; carbamylation; succinylation; carboxymethyllysination; alkylation; nitration; iodination; biotinylation; a reaction with n-bromosuccinimide, chlorosuccinimide, vicinal diketone, or glyoxal; a reaction with R-glyoxal, wherein R is selected from the group consisting of aryl, heteroaryl, lower alkyl, lower alkoxy, cycloalkyl group, and alpha-deoxyglycitolyl; or a reaction with carbodiimide followed by reaction with an amine

~~and~~

~~(b) administering to the mammal a prophylactically or therapeutically effective amount of one or more anti-inflammatory agents or immunomodulatory agents~~.

9. (Currently Amended) The method of claim 8, wherein the anti-inflammatory agent is selected from the group consisting of ~~a corticosteroid, a glucocorticoid,~~ a steroid, a non-steroidal anti-inflammatory drug, a beta-agonist, an anticholinergic agent, a methyl xanthine, gold injection, a sulphasalazine, penicillamine, an anti-angiogenic agent, dapsone, psoralen, an anti-malarial agent, an anti-viral agent, and an antibiotic.

10. (Original) The method of claim 8, wherein the immunomodulatory agent is selected from the group consisting of a proteinaceous agent, a peptide mimetic, an antibody, a nucleic acid molecule, a small molecule, an organic compound, an inorganic compound, methothrexate, leflunomide, cyclophosphamide, cytoxan, Immuran, cyclosporine A, minocycline, azathioprine, an antibiotic, methylprednisolone (MP), a corticosteroid, a steroid, mycophenolate mofetil, rapamycin, mizoribine, deoxyspergualin, brequinar, a malononitriloaminde, a T cell receptor modulator, and a cytokine receptor modulator.

11. (Canceled)

12. (Previously Amended) The method of claim 8, wherein said erythropoietin is asialoerythropoietin or phenylglyoxal-erythropoietin.

13. (Previously Amended) The method of claim 8, wherein erythropoietin is capable of traversing an endothelial cell barrier.

14. (Original) The method of claim 13, wherein the endothelial cell barrier is selected from the group consisting of blood-brain barrier, blood-eye barrier, blood-testis barrier, blood-ovary barrier, and blood-uterus barrier.

15. (Previously Amended) The method of claim 8, wherein the responsive cells are selected from the group consisting of neuronal cells, muscle cells, heart, lung, liver, kidney, small intestine, adrenal cortex, adrenal medulla, capillary cells, endothelial cells, testes, ovary, endometrial cells, and stem cells.

16. (Previously Amended) The method of claim 8, wherein the responsive cells further comprise cells selected from the group consisting of photoreceptor cells, ganglion cells, bipolar cells, horizontal cells, amacrine cells, Müeller cells, myocardium cells, pace maker cells, sinoatrial node cells, sinus node cells, atrioventricular node cells, bundle of His cells, hepatocyte cells, stellate cells, Kupffer cells, mesangial cells, goblet cells, intestinal gland cells, enteral endocrine cells, glomerulosa cells, fasciculate cells, reticularis cells, chromaffin cells, pericyte cells, Leydig cells, Sertoli cells, sperm cells, Graffian follicle cells, primordial follicle cells, endometrial stroma cells, and endometrial cells.

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin comprising a R-glyoxal moiety on the one or more arginine residues, wherein R is aryl or alkyl moiety.

25. (Original) The method of claim 24, wherein said erythropoietin is phenylglyoxal-erythropoietin.

26. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one arginine residue is modified by reaction with a vicinal diketone selected from the group consisting of 2,3-butanedione and cyclohexanedione.

27. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one arginine residue is reacted with 3-deoxyglucosone.

28. (Previously amended) The method of claim 8, wherein said erythropoietin is

an erythropoietin molecule comprising at least one biotinylated lysine or biotinylated N-terminal amino group.

29. (Previously amended) The method of claim 8, wherein said erythropoietin molecule is biotinylated.

30. (Previously amended) The method of claim 8, wherein said erythropoietin is a glucitolyl lysine erythropoietin or a fructosyl lysine erythropoietin.

31. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin having at least one carbamylated lysine residue.

32. (Original) The method of claim 31, wherein said carbamylated erythropoietin is selected from the group consisting of alpha-N-carbamoylerythropoietin; N-epsilon-carbamoylerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylerythropoietin; alpha-N-carbamoylasialoerythropoietin; N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoylhyposialoerythropoietin; N-epsilon-carbamoylhyposialoerythropoietin; and alpha-N-carbamoyl, N-epsilon-carbamoylhyposialoerythropoietin.

33. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one lysine residue is acylated.

34. (Original) The method of claim 33, wherein a lysine residue of said erythropoietin is acetylated.

35. (Original) The method of claim 34, wherein said acetylated erythropoietin is selected from the group consisting of alpha-N-acetylerythropoietin; N-epsilon-acetylerythropoietin; alpha-N-acetyl, N-epsilon-acetylerythropoietin; alpha-N-acetylasialoerythropoietin; N-epsilon- acetylasialoerythropoietin; alpha-N-acetyl, N-epsilon-acetylasialoerythropoietin; alpha-N-acetylhyposialoerythropoietin; N-epsilon-acetylhyposialoerythropoietin; and alpha-N-acetyl, N-epsilon-acetylhyposialoerythropoietin.

36. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin comprising a succinylated lysine residue.

37. (Original) The method of claim 36, where said erythropoietin is selected from the group consisting of alpha-N-succinylerythropoietin; N-epsilon-succinylerythropoietin; alpha-N-succinyl, N-epsilon-succinylerythropoietin: alpha-N-succinylasialoerythropoietin; N-epsilon-succinylasialoerythropoietin; alpha-N-succinyl. N-

epsilon-succinylasialoerythropoietin; alpha-N-succinylhyposialoerythropoietin; N-epsilon-succinylhyposialoerythropoietin; and alpha-N-succinyl, N-epsilon-succinylhyposialoerythropoietin.

38. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin with at least one lysine residue modified by a 2, 4, 6-trinitrobenzenesulfonic acid salt.

39. (Previously amended) The method of claim 38, wherein the salt is 2, 4, 6-trinitrobenzenesulfonate sodium.

40. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin in which at least one tyrosine residue is nitrated and/or iodinated.

41. (Previously amended) The method of claim 8, wherein said erythropoietin is an erythropoietin in which an aspartic acid and/or glutamic acid residue is reacted with a carbodiimide followed by reaction with an amine.

42. (Original) The method of claim 41, wherein said amine is glycinamide.

43. (Previously amended) The method of claim 8, wherein the inflammatory disease results from a disease condition or trauma.

44. (Previously amended) The method of claim 8, wherein the inflammation is selected from the group consisting of angiitis, chronic bronchitis, pancreatitis, osteomylitis, rheumatoid arthritis, glomerulonephritis, optic neuritis, temporal arteritis, encephalitis, meningitis, transverse myelitis, dermatomyositis, polymyositis, necrotizing fascilitis, hepatitis, and necrotizing enterocolitis.

45. (Previously amended) The method of claim 8, wherein the erythropoietin inhibits inflammation resulting from cytokines produced by glial cells.

46. (Previously presented)The method of claim 8, wherein the inflammation is triggered by apoptosis.

47-52. (Cancelled).

53. (Previously amended) The method of claim 8, wherein said erythropoietin is an alpha-N-carbamoyl, N-epsilon-carbamoylerythropoietin.

54. (Previously amended) The method of claim 8, wherein said erythropoietin is non-erythropoietic.

55. (Previously Presented) The method of claim 8, wherein the erythropoietin and the anti-inflammatory agent or immunomodulatory agent are administered to the mammal concurrently.

56. (New) A method for treating an inflammatory disease in a mammal comprising administering to a mammal in need thereof a prophylactically or therapeutically effective amount of a chemically modified erythropoietin,

wherein said chemically modified erythropoietin has a reduced level of in vivo erythropoietic activity compared to native erythropoietin as determined by the exhypoxic polycythemic mouse bioassay, and has tissue protective activity in vivo as determined by the middle cerebral artery occlusion test,

and wherein said chemically modified erythropoietin comprises:

i) a chemically modified arginine residue at position 31, 37, 41, 80, 103, 130, 137, 158, 166, 170, 177, 189, or 193 of SEQ ID NO:5;

ii) a chemically modified lysine residue at position 47, 72, 79, 124, 143, 167, 179, or 181 of SEQ ID NO:5 or a chemically modified N-terminal amino group;

iii) a chemically modified tyrosine residue at position 42, 76, 172, or 183 of SEQ ID NO:5;

iv) a chemically modified aspartic acid residue at position 35, 70, 123, 150, 163, or 192 of SEQ ID NO:5;

v) a chemically modified glutamic acid residue at position 40, 45, 48, 50, 58, 64, 82, 89, 99, 116, 144, or 186 of SEQ ID NO:5; or

vi) a chemically modified tryptophan residue at position 78, 91, or 115 of SEQ ID NO:5,

wherein the chemical modification results from one of the following chemical reactions: acetylation; carbamylation; succinylation; carboxymethyllysination; alkylation; nitration; iodination; biotinylation; a reaction with n-bromosuccinimide, chlorosuccinimide, vicinal diketone, or glyoxal; a reaction with R-glyoxal wherein R is selected from the group consisting of aryl, heteroaryl, lower alkyl, lower alkoxy, cycloalkyl group, and alpha-deoxyglycitolyl; or a reaction with carbodiimide followed by reaction with an amine.

57. (New) The method of claim 56, wherein said erythropoietin is an

erythropoietin having at least one carbamylated lysine residue.

58. (New) The method of claim 57, wherein said carbamylated erythropoietin is selected from the group consisting of alpha-N-carbamoylerythropoietin; N-epsilon-carbamoylerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylerythropoietin; alpha-N-carbamoylasialoerythropoietin; N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoyl, N-epsilon-carbamoylasialoerythropoietin; alpha-N-carbamoylhyposialoerythropoietin; N-epsilon-carbamoylhyposialoerythropoietin; and alpha-N-carbamoyl, N-epsilon-carbamoylhyposialoerythropoietin.

59. (New) The method of claim 56, wherein said erythropoietin is non-erythropoietic.